Cristália Produtos Químicos Farmacêuticos Ltda.

This early-stage trial tests whether a single dose of CRIS100 is safe for people with a recent thoracic spinal cord injury. Five adults aged 18-70 will receive the drug directly at the injury site within 72 hours of their accident. The study focuses on side effects and lab change…

This early-stage study tests whether a new liposome-based antidote is safe in 12 healthy adults aged 18 to 30. Participants receive a single dose and are monitored for side effects and how the drug moves through the body. The goal is to gather safety information, not to treat any…